|
|
| | Neostigmine Methyl Sulfate Basic information |
| | Neostigmine Methyl Sulfate Chemical Properties |
| Melting point | 175-177 °C(lit.) | | storage temp. | -20°C | | solubility | H2O: 1 g/mL | | form | powder | | color | white | | Water Solubility | 1g/10mL | | Merck | 14,6464 | | CAS DataBase Reference | 51-60-5(CAS DataBase Reference) |
| Hazard Codes | T+ | | Risk Statements | 28-36/37/38-42/43-26/27/28 | | Safety Statements | 36-45-36/37/39-28A | | RIDADR | UN 2811 6.1/PG 2 | | WGK Germany | 3 | | RTECS | CY1225000 | | HazardClass | 6.1(a) | | PackingGroup | II | | HS Code | 29242990 | | Toxicity | LD50 in mice (mg/kg): 0.16 i.v.; 0.42 s.c.; 7.5 orally, (Randall, Lehmann) |
| | Neostigmine Methyl Sulfate Usage And Synthesis |
| Description | Neostigmine is a reversible inhibitor of acetylcholinesterase (AChE; Kd = 260 μM). In a rat model of knee joint inflammation, intrathecal administration of neostigmine (2-30 μg) increases endogenous acetylcholine levels and dose-dependently increases the latency of paw withdrawal in response to thermal and mechanical stimuli (ED50s = 6.6 and 3.5 μg, respectively). Neostigmine (5 μg, i.p.) restores muscle action potentials in mice with a thymopoietin-induced neuromuscular block. Formulations containing neostigmine have been used in the treatment of myasthenia gravis and Ogilvie syndrome. | | Chemical Properties | Crystalline Solid | | Uses | Cholinergic; miotic; antidote (curare) | | Definition | ChEBI: Neostigmine methyl sulfate is an arylammonium sulfate salt. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor. | | Brand name | Prostigmine (ICN). | | General Description | Neostigmine methylsulfate,(m-hydroxyphenyl)trimethylammonium methylsulfatedimethylcarbamate or the dimethylcarbamic ester of 3-hydroxyphenyltrimethylammoniummethylsulfate (Prostigminmethylsulfate), is a bitter, odorless, white, crystalline powder.It is very soluble in water and soluble in alcohol. Solutionsare stable and can be sterilized by boiling. The compound istoo hygroscopic for use in a solid form and thus is alwaysused as an injection. Aqueous solutions are neutral to litmus. | | Clinical Use | The methylsulfate salt is used postoperatively as a urinarystimulant and in the diagnosis and treatment of myastheniagravis. | | Purification Methods | Crystallise the sulfate from EtOH or Me2CO (m 143-144o). Its solubility in H2O is ~10%. [Beilstein 13 III 939.] (It is cholinergic and highly TOXIC.) |
| | Neostigmine Methyl Sulfate Preparation Products And Raw materials |
|